Inventor · disambiguated record
Thomas Mccauley
Also filed as: MCCAULEY THOMAS · MCCAULEY THOMAS G · MCCAULEY THOMAS GREENE
30 granted patents·15 pending applications·282 citations·filing 2002–2025
97Inventor score
Files withSHIRE HUMAN GENETIC THERAPIES7ARCHEMIX LLC6ARCHEMIX CORP5INOTEK PHARMACEUTICALS CORP5KIM NORMAN N4
Top patents by PatentIndex Score
45 records- 0193US7538211B2Aptamer therapeutics useful in the treatment of complement-related disordersARCHEMIX CORP·Filed 2005·Granted May 26, 2009·33 cites·7 claims
- 0292US7803931B2Aptamer therapeutics useful in the treatment of complement-related disordersARCHEMIX CORP·Filed 2005·Granted Sep 28, 2010·19 cites·5 claims
- 0392US7579456B2Aptamer therapeutics useful in the treatment of complement-related disordersARCHEMIX CORP·Filed 2006·Granted Aug 25, 2009·24 cites·6 claims
- 0492US2025375506A1Cns delivery of therapeutic agentsTAKEDA PHARMACEUTICALS CO·Filed 2025·Application pending·0 cites
- 0591US10456454B2CNS delivery of therapeutic agentsSHIRE HUMAN GENETIC THERAPIES·Filed 2016·Granted Oct 29, 2019·6 cites·27 claims
- 0691US9283181B2CNS delivery of therapeutic agentsCALIAS PERICLES·Filed 2011·Granted Mar 15, 2016·34 cites·6 claims
- 0790US7125660B2Nucleic acid sensor molecules and methods of using sameARCHEMIX CORP·Filed 2002·Granted Oct 24, 2006·77 cites·54 claims
- 0889US11471516B2CNS delivery of therapeutic agentsSHIRE HUMAN GENETIC THERAPIES·Filed 2019·Granted Oct 18, 2022·1 cites·17 claims
- 0989US11167043B2Composition and methods for treatment of ornithine transcarbamylase deficiencyTRANSLATE BIO INC·Filed 2018·Granted Nov 9, 2021·4 cites·4 claims
- 1088US8440639B2Combination compositions for reducing intraocular pressureKIM NORMAN N·Filed 2011·Granted May 14, 2013·8 cites·31 claims
- 1188US8236773B2Aptamer therapeutics useful in the treatment of complement-related disordersBENEDICT CLAUDE·Filed 2006·Granted Aug 7, 2012·9 cites·10 claims
- 1287US10947544B2Aptamer therapeutics useful in the treatment of complement-related disordersARCHEMIX LLC·Filed 2019·Granted Mar 16, 2021·1 cites·5 claims
- 1387US8476247B2Method of reducing intraocular pressure in humansKIM NORMAN N·Filed 2011·Granted Jul 2, 2013·10 cites·19 claims
- 1486US8895530B2Method of reducing intraocular pressure in humansINOTEK PHARMACEUTICALS CORP·Filed 2013·Granted Nov 25, 2014·7 cites·20 claims
- 1586US8436164B2Aptamer therapeutics useful in the treatment of complement-related disordersBENEDICT CLAUDE·Filed 2012·Granted May 7, 2013·6 cites·15 claims
- 1685US12409210B2CNS delivery of therapeutic agentsTAKEDA PHARMACEUTICALS CO·Filed 2022·Granted Sep 9, 2025·0 cites·5 claims
- 1784US9617546B2Aptamer therapeutics useful in the treatment of complement-related disordersARCHEMIX LLC·Filed 2014·Granted Apr 11, 2017·4 cites·5 claims
- 1884US8877732B2Combination, kit and method of reducing intraocular pressureKIM NORMAN N·Filed 2011·Granted Nov 4, 2014·8 cites·14 claims
- 1983US9289383B2Method of reducing intraocular pressure in humansINOTEK PHARMACEUTICALS CORP·Filed 2014·Granted Mar 22, 2016·4 cites·28 claims
- 2082US8455457B2Combination compositions for reducing intraocular pressureKIM NORMAN N·Filed 2011·Granted Jun 4, 2013·8 cites·31 claims
- 2180US9682129B2Treatment of cognitive impairment of hunter syndrome by intrathecal delivery of iduronate-2-sulfataseSHIRE HUMAN GENETIC THERAPIES·Filed 2012·Granted Jun 20, 2017·5 cites·29 claims
- 2279US8039443B2Stabilized aptamers to platelet derived growth factor and their use as oncology therapeuticsARCHEMIX CORP·Filed 2004·Granted Oct 18, 2011·5 cites·3 claims
- 2377US11913000B2Aptamer therapeutics useful in the treatment of complement-related disordersIVERIC BIO INC·Filed 2021·Granted Feb 27, 2024·0 cites·10 claims
- 2475US8946184B2Aptamer therapeutics useful in the treatment of complement-related disordersARCHEMIX LLC·Filed 2013·Granted Feb 3, 2015·1 cites·20 claims
- 2574US10100316B2Aptamers comprising CPG motifsEPSTEIN DAVID·Filed 2004·Granted Oct 16, 2018·4 cites·14 claims
- 2672US12268754B2Composition and methods for treatment of ornithine transcarbamylase deficiencyTRANSLATE BIO INC·Filed 2021·Granted Apr 8, 2025·0 cites·18 claims
- 2772US10568941B2Treatment of cognitive impairment of Hunter syndrome by intrathecal delivery of iduronate-2-sulfataseSHIRE HUMAN GENETIC THERAPIES·Filed 2017·Granted Feb 25, 2020·1 cites·10 claims
- 2870US9603908B2Subcutaneous administration of iduronate-2-sulfataseSHIRE HUMAN GENETIC THERAPIES·Filed 2013·Granted Mar 28, 2017·2 cites·24 claims
- 2970US9370530B2Combination, kit and method of reducing intraocular pressureINOTEK PHARMACEUTICALS CORP·Filed 2014·Granted Jun 21, 2016·1 cites·25 claims
- 3067US11357832B2Treatment of cognitive impairment of hunter syndrome by intrathecal delivery of iduronate-2-sulfataseTAKEDA PHARMACEUTICALS CO·Filed 2020·Granted Jun 14, 2022·0 cites·17 claims
- 3164US2025152739A1Composition and methods for treatment of ornithine transcarbamylase deficiencyTRANSLATE BIO INC·Filed 2025·Application pending·0 cites
- 3263US2015140120A1Stabilized aptamers to platelet derived growth factor and their use as oncology therapeuticsARCHEMIX LLC·Filed 2014·Application pending·0 cites
- 3362US2018030446A1Aptamer therapeutics useful in the treatment of complement-related disordersARCHEMIX LLC·Filed 2017·Application pending·0 cites
- 3457US8853376B2Stabilized aptamers to platelet derived growth factor and their use as oncology therapeuticsMCCAULEY DILARA·Filed 2011·Granted Oct 7, 2014·0 cites·9 claims
- 3555US2016053266A1Stabilized Aptamers to Platelet Derived Growth Factor and Their Use as Oncology TherapeuticsARCHEMIX LLC·Filed 2015·Application pending·0 cites
- 3653US2016158268A1Method of reducing intraocular pressure in humansINOTEK PHARMACEUTICALS CORP·Filed 2016·Application pending·0 cites
- 3752US2009053138A1Stabilized Aptamers to Platelet Derived Growth Factor and their Use as Oncology TherapeuticsPREISS JEFFREY R·Filed 2005·Application pending·0 cites
- 3850US2004253243A1Aptamer therapeutics useful in ocular pharmacotherapyFiled 2004·Application pending·0 cites
- 3949US2016367586A1Combination, kit and method of reducing intraocular pressureINOTEK PHARMACEUTICALS CORP·Filed 2016·Application pending·0 cites
- 4049US2005124565A1Stabilized aptamers to platelet derived growth factor and their use as oncology therapeuticsFiled 2004·Application pending·0 cites
- 4148US2013295071A1Methods and compositions for cns delivery of b-galactocerebrosidaseSHIRE HUMAN GENETIC THERAPIES·Filed 2013·Application pending·0 cites
- 4242US2016030416A1Methods of treating b2-bradykinin receptor mediated angioedemaSHIRE HUMAN GENETIC THERAPIES·Filed 2014·Application pending·0 cites
- 4341US2006030535A1Controlled modulation of the pharmacokinetics and biodistribution of aptamer therapeuticsHEALY JUDITH M·Filed 2005·Application pending·0 cites
- 4440US2011318324A1Methods and compositions for cns delivery of b-galactocerebrosidaseSALAMAT-MILLER NAZILA·Filed 2011·Application pending·0 cites
- 4536US2020009130A1Ocular distribution and pharmacokinetics of lifitegrast formulationsSARCODE BIOSCIENCE INC·Filed 2017·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →